Mesa Laboratories Inc logo

Mesa Laboratories Inc(MLAB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$139.01
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MLAB

11/13/2026: MLAB (2-star) is currently NOT-A-BUY. Pass it for now.

Mesa Laboratories is a specialized provider of quality control and compliance instruments primarily for the pharmaceutical and healthcare industries. The company has a leading position in niche segments, known for strong margins driven by a steady stream of recurring revenue from consumable products. Its growth strategy relies heavily on the disciplined acquisition of high-value businesses, which presents both a primary opportunity for scaling and a risk regarding integration and execution. Investors must consider its valuation premiums and reliance on the M&A cycle. Mesa may suit growth-oriented investors, though it is less suitable for those prioritizing dividends. Key developments to monitor include acquisition performance and organic margin improvement.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company consistently pursues top-line growth through disciplined acquisition strategies.
Momentum investorMixed fitPerformance is highly dependent on market cycles and integration success, requiring careful timing.
Value investorMixed fitValuation is often premium due to growth expectations, making entry price sensitive.
Dividend investorWeak fitThe company prioritizes capital reinvestment over significant dividend yield.
Low-risk investorWeak fitAcquisition-driven business models carry integration and financial leverage risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock often reacts significantly to acquisition announcements and integration milestones.
Valuation riskMediumMarket expectations for growth can sometimes outpace actual earnings results.
Competition risk (Life Sciences Tools)Medium / highLarger players like 3M and STERIS have more resources to invest in R&D and distribution.
Business qualityStrongHigh margins and recurring revenue from consumables create a durable franchise quality.
Dividend incomeLowThis is not an income-oriented investment.
Execution riskMedium / highThe success of the business model depends entirely on identifying and integrating new companies effectively.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 781.31M USD
Price to earnings Ratio 119.84
1Y Target Price 150
Price to earnings Ratio 119.84
1Y Target Price 150
Volume (30-day avg) 104.9K shares
Beta 1.08
52 Weeks Range 69.06 - 144.35
Updated Date 11/14/2026
52 Weeks Range 69.06 - 144.35
Updated Date 11/14/2026
Dividends yield (FY) 0.47%
Basic EPS (TTM) 1.16

Sector & Industry Intelligence

Sector

Technology

Caution
Sentiment
Near Bearish
Momentum
Rapid Breadth Deterioration
BUY participation
30.1%
Active BUY / eligible
37 / 123
30-Day BUY Count Change
-42
Market state
Weak Bullish / Near Bearish

BUY participation is falling rapidly, suggesting elevated market vulnerability.

Industry

Scientific & Technical Instruments

BUY participation
0.0%
Active BUY / eligible
0 / 4
30-Day BUY Count Change
-2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -58.9%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MLAB receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
MLAB has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and strong ownership. In FY2026 versus FY2025, strong earnings growth (+440.0%) and strong cash generation (FCF margin 15.9%) are partially offset by moderate revenue growth (+3.4%), soft profitability (net margin 2.7%).

Financial Health Rating

★★★★★
MLAB's financial health is supported by solid cash strength, including free-cash-flow generation (15.9% of revenue). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is MLAB's strongest growth driver at +440.0% FY2026 versus FY2025 (strong, 5 stars). By comparison, while revenue growth (+3.4%, moderate) and free-cash-flow growth (-6.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 100.4% and approximately 88.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 5.57% supports management-shareholder alignment.

Top 5 Institutional Investors

Long Path Partners, LP 8.53%
BlackRock Inc 7.87%
Boston Partners Global Investors, Inc 4.74%
Vanguard Capital Management, LLC 4.24%
AQR Capital Management LLC 3.64%

Unit Economics (Per $1K Revenue)

★★★★★
MLAB generates approximately $635 of gross profit, $74 of operating income, and $159 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Moderate margins and strong cash conversion support a 3-star rating, while capital efficiency is weak.

Economic Dimensions

★★★★★
Effective Tax Rate: 44.13%

Quantitative Style Profile

★★★★★
MLAB has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Consumables (Sterilization/Validation)Biological and chemical indicators sold to recurring customer base.Steady revenue generated by products that customers need to replace frequently.
Instruments/CalibrationAirflow calibrators, data loggers, and sensors.Higher-priced, durable equipment sold to labs and factories for quality compliance.
Geography (International vs Domestic)Sales across North America, Europe, and Asia.Global regulatory trends drive demand regardless of local economic conditions.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-09
When After Market
Estimate 2.24
Actual 1.22

Profitability

Profit Margin 2.65%
Operating Margin (TTM) 10.4%

Management Effectiveness

Return on Assets (TTM) 3.9%
Return on Equity (TTM) 3.57%

Valuation

Trailing PE 119.84
Forward PE 35.21
Enterprise Value 871.33M
Price to Sales(TTM) 3.11
Enterprise Value 871.33M
Price to Sales(TTM) 3.11
Enterprise Value to Revenue 3.47
Enterprise Value to EBITDA 18.86
Shares Outstanding 5.62M
Shares Floating 4.97M
Shares Outstanding 5.62M
Shares Floating 4.97M
Percent Insiders 5.57
Percent Institutions 100.43

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.